Showing results (1-10 of 43) with videos related to
Sort By:
Pageof 5
Expert Opinion on Investigational Drugs|December 21, 2012
Perifosine in renal cell carcinomaNeeharika Srivastava, Daniel C ChoCancer Management and Research|July 15, 2014
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscapeNeeharika Srivastava, David McDermottBiotechnology Research International|January 11, 2013
Isolation and characterization of some phytochemicals from Indian traditional plantsNeeharika Srivastava, Aishwarya Singh Chauhan, Bechan SharmaThe American Journal of Hospice & Palliative Care|December 28, 2018
Timely Referral to Hospice Care for Oncology Patients: A Retrospective ReviewAndrew K Mulville, Nancy N Widick, Neeharika Srivastava MakaniBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2014
Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlookDaniel C ChoClinical Practice (London, England)|February 5, 2013
Therapeutic challenges in advanced renal cell carcinomaDaniel C ChoOncotargets and Therapy|June 22, 2013
Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitorsDaniel C ChoAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Novel Therapeutics Affecting Metabolic PathwaysSalman Punekar, Daniel C ChoTherapy (London, England : 2004)|September 7, 2011
mTOR inhibitors in renal cell carcinomaChiara Battelli, Daniel C ChoClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B AtkinsPageof 5